Thomas Clozel, Angel Investor

Thomas Clozel is CEO and Co‑Founder of OWKIN, an AI‑driven precision medicine company pioneering federated learning on patient data to accelerate drug discovery and improve clinical outcomes. Since 2016, OWKIN has partnered with leading medical institutions and pharmaceutical companies to build collective intelligence while preserving data privacy and security. He is also a non‑operational co‑founder of Bioptimus and Cure51, contributes to the XPRIZE Brain Trust, and serves on the Board of Directors of Université Paris‑Saclay, reflecting his broader commitment to advancing science, entrepreneurship, and global innovation. As an investor, his portfolio includes Altrove AI, Grâce, Callyope, Osium AI, Dioxycle, Resilience, Spot, and Patch Biosciences, highlighting his focus on AI, biotech, and climate innovation.